TheAnswerPage

NOVEMBER 29, 2021

What serious adverse events have been noted in psilocybin clinical trials? The serious adverse events (AE) reported in the psilocybin clinical trial conducted by Compass Pathways occurred in 12 of the 233 patients and included suicidal behavior, suicidal ideation, and intentional self-injury.

Clinical Trials 52

Clinical Trials Events Patients 52

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 8, 2021

Enveric Enters into Clinical Stage Development of Lead Asset, EV101, in Israel with MOH Approval. “Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.”

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. Brett Maas.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

SEPTEMBER 22, 2021

Pnina Fishman will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021 and will join a panel discussion regarding medical cannabis. Date: Wednesday, September 29, 2021. Date: Wednesday, September 29, 2021. Details are below: Medical Cannabis Panel. Time: 11:55 am – 12:35 pm ET. To view live: link.

Clinical Trials 52

Clinical Trials Treatment Business Events 52

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF ), ( Bionomics ) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares ( ADSs ) in the United States and a concurrent listing of ADSs on Nasdaq.

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Highlights from the presentation include: Declining PSA levels in treated patients. Phase 2 trial underway. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

AUGUST 2, 2021

2, 2021 /PRNewswire/ — SciSparc Ltd. OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We On July 30, 2021, Virpax announced the appointment of Gerald W. On August 17, 2021, Virpax announced that it had received FDA response and guidance on AnQlar.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JUNE 14, 2022

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector. The good news is that innovations that completely change the lives of patients continue to emerge.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 1, 2021

The findings have been published in an abstract in the October 2021 supplement of HEPATOLOGY , a premier peer-reviewed publication in the field of liver disease published on behalf of the AASLD. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. Can-Fite BioPharma.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. About Oravax Medical.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

AUGUST 24, 2021

Thus, there is a great need to develop new and effective therapeutics for treating patients. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease and decline rather than only addressing the symptoms.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

DECEMBER 9, 2021

Thu, December 9, 2021, . 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. In one particular group, all patients showed consistent results across multiple genomic analyses. Forward-looking statements are statements that relate to future, not past, events.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. royalty on all future net sales.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Case Context.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

AUGUST 26, 2022

Apart from this, various clinical trials are done for multiple conditions. billion in 2021. The triggers are events that happen before the seizure starts. According to the result, it was revealed that patients taking a 20 mg/kg/d of CBD regimen noticed a 41.9 It has been predicted to reach about $47.22

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JULY 7, 2021

Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed by MyMD on May 18, 2021.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

JULY 28, 2021

Advance to FDA IND-enabling studies to support human clinical studies. – July 28, 2021) – PharmaDrug Inc. Based on these promising findings, PharmaDrug reiterates that it remains committed to the clinical development of PD-001 for the treatment of patients suffering from esophageal cancer. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Healer

DECEMBER 17, 2021

November 5, 2021. Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen. By Dr. Dustin Sulak. topiramate.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 28, 2021

.–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I Mack, Chairman and CEO of Virpax. to conduct this study in Canada.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. Stolar & Ilan Matok. Metrics details.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

JULY 9, 2021

Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S.

Data 105

Data Clinical Trials Decriminalization Hemp 105